Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Oral Oncol. 2017 Dec 23;77:83–89. doi: 10.1016/j.oraloncology.2017.12.003

Table 2.

Antibody Staining of Patient Cohort

Stain Intensity Patients
PDL1 0 161 (99%)
≥1 1 (1%)
p16 0 153 (95%)
≥1 8 (5%)
CD31 0 85 (53%)
≥1.5 76 (47%)
Vimentin 0 122 (71%)
≥1 50 (29%)
EGFR 0 1 (1%)
1 10 (6%)
2 17 (10%)
3 146 (84%)
p53 0 73 (42%)
1 13 (8%)
2 13 (8%)
3 73 (42%)